On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.
Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania
Episode Topics1:48 What’s the difference between the FDA and Centers for Medicare and Medicaid Services?
3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possible the proposal could change?
9:09 What are your key takeaways from the CMS proposal?
11:58 Who’s being charged the cost of the treatment if it is part of a clinical trial?
18:33 What does this decision, with its focus on research often occurring in major urban medical centers, mean for equity and access?
26:27 What is the future of Alzheimer’s disease research after the CMS decision?
Show NotesRead the Center for Medicare and Medicaid Services’s press release about the proposed coverage policy, view submitted public comments about the decision, and submit your own comment.
Learn more about Dr. Jason Karlawish’s work and writing at his website.
Listen to our four-part episode series with Dr. Jason Karlawish about his book, The Problem of Alzheimer’s, on our website (episode 1, episode 2, episode 3, episode 4).
Making an IMPACT: Advancing Alzheimer’s Disease Clinical Trials Through Workforce Development and Inclusivity
Living with Lewy Body: A Neurologist’s Journey Through Research and Dementia Care
The Fundamentals of Neuropsychology: Breaking Down Cognition, Memory and More
Long COVID and Its Effect on Cognition
Listen Up! The Connections Between Hearing Loss, Hearing Interventions and Cognitive Decline
From Caregiver to Research Participant: How One Woman’s Experience as a Dementia Caregiver Drew Her to Alzheimer’s Research
Looking at Lecanemab’s Eligibility Guidelines and Prescription Process
Do Non-Medicinal Interventions Reduce Dementia Risk? Studies are Inconclusive, Here’s Why
The Road to Hope: Philanthropy’s Impact on Alzheimer’s Research
Could Green Tea Hold the Key to New Alzheimer’s Treatments?
The Impact of Social Isolation on Dementia Risk in Older Adults
Memories and Milestones: Celebrating Six Years of ‘Dementia Matters’
Crosswords or Computers: Which is Better for Cognitive Engagement?
RAISE(ing) Support for Caregivers: State and National Resources for Family Care Partners
Mental Health and Memory: The Connections between Chronic Mental Illness and Dementia
Highlights from the 2023 Alzheimer’s Association International Conference
A Fair Fight Against Alzheimer’s: The Need for Equity in Dementia Research and Care
Agitation and Alzheimer’s: Strategies for Managing Behavioral and Psychological Symptoms of Dementia
Promises to Practice: Creating Sustainable Community Partnerships to Support Alzheimer’s Research
Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations
Create your
podcast in
minutes
It is Free
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks